ZURICH, Dec 2 (Reuters) – Actelion’s silence speaks volumes
to the dozens of event-driven hedge funds piling into the Swiss
biotech firm, betting that Johnson & Johnson’s (J&J)
approach will result…
The post RPT-Actelion’s silence has hedge funds betting big on J&J deal appeared first on NASDAQ.